ImmunAbs Inc. Announces US FDA Approval for a Phase 1 Clinical Trial

2022年08月06日 13:35:30 来自: (0)参与

SEOUL, South Korea -- (BUSINESS WIRE) --

ImmunAbs Inc. (www.immunabs.com) announced that it has received US FDA approval for a Phase 1 clinical trial and that it is now ready to initiate a phase 1 clinical trial in the United States.

ImmunAbs is developing IM-101, a monoclonal antibody targeting complements that play essential roles in the immune system but, when out of regulation, cause various autoimmune diseases, including but not limited to paroxysmal nocturnal hemoglobinuria (PNH). The complement inhibitors drug market showed its growth potential by achieving an average annual growth rate of 20.7% and a market size of USD $ 5.1 billion in 2020 and is expected to grow to USD $19 billion by 2027.

Paroxysmal nocturnal hemoglobinuria is one example of complement-mediated autoimmune diseases where the membrane proteins protecting the red blood cells from complement activation are lost due to mutations, which results in red blood cells being destructed by the complements. Due to insufficient inhibition of complements shown by currently approved complement inhibitors, Soliris and Ultomiris, patients who receive these drugs still suffer from the residual symptoms of PNH, which include anaemia, fatigue, and decreased productivity at work.

ImmunAbs’ new complement therapeutic IM-101 targets the safest and most potent component of the complement system, complement C5. IM-101 has been shown to completely inhibit complement activation, and thus is expected to alleviate the symptoms that persist with the standard of care. ImmunAbs will initiate a phase 2a clinical trial in the United States in 2024.

“This is a historical milestone for ImmunAbs.” said Dr. DongJo Kim, the company’s CEO. “We are delighted to see IM-101’s efficacy in humans which has been proven in our ex vivo study. We hope that our IM-101 will reach patients who may suffer from symptoms that persist due to insufficient complement inhibition by the current treatments.”

About ImmunAbs Inc.

ImmunAbs Inc. was established in 2017 by experts of global standard antibody therapeutics development. The vision is "Hope for Patients, Dreams for All." Currently, ImmunAbs has several antibody therapeutics in global standard development for autoimmune diseases, diabetic retinopathy, and metabolic syndrome. ImmunAbs successfully raised KRW 18.1 billion from Seed to series A funding in 2021 and got a non-clinical study national grant for developing IM-101 from Korea Drug Development Fund in November last year.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220803005380/en/

CONTACT:

HyunJung Jung
Business Development Manager
Hyunjung.Jung@ImmunAbs.com

相关新闻
其它网友:旧情歌-TRISTE
评论:我还没年轻到什么都懂的地步。

猫扑网友:-旧流年 seven ||
评论:虎落平阳被犬欺、落配凤凰不如鸡 。

搜狐网友:哥只是寂寞
评论:从小就有一个敌人叫“别人家的小孩”。他不爱玩游戏,从来只知道学习。

天猫网友:一个2B的男人
评论:古希腊人说过:能让我笑得人最爱我,能让我哭的人我最爱。

百度网友:WinNer丶哭声
评论:长大成人这件事最恐怖的地方之一,在于,你或许会变成自己曾经最看不起的那种人。

本网网友:邪念 L1uo -
评论:装傻这事,如果干的好,叫大智若愚

淘宝网友:我會很愛你
评论:我的优点:勇于认错;缺点:坚决不改。

网易网友:俄徹底心灰
评论:快开学了,学校,你得到的我的人却得不到我的心。

腾讯网友:漃寞啲男亼ぃ
评论:你打扮成这样,是对这个世界有什么不满吗?

天涯网友:THOMAS 《死亡诗社》
评论:所谓长大、就是把原本看重的东西看轻一点、原本看轻的东西看重点...

新闻转自网络媒体,如有侵权,请与我们联系:1160322105@qq.com责编:admin